Anti-Human PD-L1 Recombinant Antibody (2.7A4) (HV974023)

Name: Anti-Human PD-L1 Recombinant Antibody (2.7A4)
Brand: abinScience
SKU: HV974023
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HV974023

Reactividad de especies

Human

Aplicaciones

Blocking, ELISA, FCM

Especie huésped

Mouse

Clonalidad

Monoclonal

Isotipo

IgG2a, lambda

ID de clon

2.7A4

Objetivo

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

Q9NZQ7

RRID

Anti-Human CD274/PD-L1/B7-H1 Antibody (2.7A4) (abinScience Cat# HV974023, RRID:AB_3725373)

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

Nota

For research use only.

Isotype Control

Mouse IgG2a (Fc Silence) Recombinant Isotype Control (MOPC 173) (MF533023)

Imágenes